Display options
Cite
Martin S, Dudek-Perić AM, Maes H, et al. Corrigendum to "Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells" [Biochem. Pharmacol. 93 (3) (2015) 290-304]. Biochem Pharmacol. 2020;175:113810doi: 10.1016/j.bcp.2020.113810.
Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2020). Corrigendum to "Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells" [Biochem. Pharmacol. 93 (3) (2015) 290-304]. Biochemical pharmacology, 175113810. https://doi.org/10.1016/j.bcp.2020.113810
Martin, S, et al. "Corrigendum to "Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells" [Biochem. Pharmacol. 93 (3) (2015) 290-304]." Biochemical pharmacology vol. 175 (2020): 113810. doi: https://doi.org/10.1016/j.bcp.2020.113810
Martin S, Dudek-Perić AM, Maes H, Garg AD, Gabrysiak M, Demirsoy S, Swinnen JV, Agostinis P. Corrigendum to "Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells" [Biochem. Pharmacol. 93 (3) (2015) 290-304]. Biochem Pharmacol. 2020 May;175:113810. doi: 10.1016/j.bcp.2020.113810. Epub 2020 Feb 19. PMID: 32085947.
Copy Download .nbib Format: NLM
Share it on

Biochem Pharmacol. 2020 May;175:113810. doi: 10.1016/j.bcp.2020.113810. Epub 2020 Feb 19.

Corrigendum to "Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells" [Biochem. Pharmacol. 93 (3) (2015) 290-304].

Biochemical pharmacology

S Martin, A M Dudek-Perić, H Maes, A D Garg, M Gabrysiak, S Demirsoy, J V Swinnen, P Agostinis

Affiliations

  1. Cell Death Research and Therapy Unit, Department for Cellular and Molecular Medicine, University of Leuven (KU Leuven), Campus Gasthuisberg, O&N1, Herestraat 49, Box 802, 3000 Leuven, Belgium.
  2. Laboratory of Lipid Metabolism and Cancer, Department of Oncology, University of Leuven (KU Leuven), Campus Gasthuisberg, O&N1, Herestraat 49, Box 818, 3000 Leuven, Belgium.
  3. Cell Death Research and Therapy Unit, Department for Cellular and Molecular Medicine, University of Leuven (KU Leuven), Campus Gasthuisberg, O&N1, Herestraat 49, Box 802, 3000 Leuven, Belgium. Electronic address: [email protected].

PMID: 32085947 DOI: 10.1016/j.bcp.2020.113810

[No abstract available.]

Publication Types